Eye drops of 1% prednisolone acetate, 1% atropine, and tropicamide were used.
眼部滴用1%百力特、1%阿托品和复方托品酰胺眼液。
Result: there is no difference on mydriasis in these groups by dripping tropicamide eyedrops(P<0.05).
两组点扩瞳剂托吡卡胺滴眼液后扩瞳效果无统计学意义（P >0 .0 5 ）。
Objective: to compare the mydriasis effect of lifting up eyelid superior or not as using tropicamide eyedrop.
比较点扩瞳剂托吡卡胺滴眼液时提上睑与否对其扩瞳效果的影响。
Methods Use the Tropicamide eye Drops to drip to the eyes, check it every month, and one course of treatment was one year.
方法用双星明眼水交替点眼，每月检查一次，一年一个疗程。
Conclusion: it showed that tropicamide eyedrops has little influence on mydriasis whether uplifting eyelid of patients or not.
提起上睑与否对托吡卡胺滴眼液的扩瞳效果影响不大。
Objective to compare the effects of cyclopentolate hydrochloride, compound tropicamide and atropine on cycloplegia in children.
目的比较盐酸环喷托酯、复方托吡卡胺与阿托品对儿童验光中睫状肌麻痹的效果。
Conclusion the application of neostigmine accompanied with tropicamide is a reliable therapy for treatment of the progressing myopia in adolescent.
结论采用新斯的明联合复方托吡卡胺是治疗青少年进行性近视患者的一种可靠方法。
CONCLUSION: Compound tropicamide is shown to be an ideal drug for mydriatic optometry in juvenile patients of 12-15 years old, but not necessary for patients between 16 and 18 years old.
结论：复方托品酰胺是较大年龄(12 ~ 15岁)儿童散瞳验光的理想药物，而对16 ~18岁年龄段青少年可以直接小瞳验光。
CONCLUSION: Compound tropicamide is shown to be an ideal drug for mydriatic optometry in juvenile patients of 12-15 years old, but not necessary for patients between 16 and 18 years old.
结论：复方托品酰胺是较大年龄(12 ~ 15岁)儿童散瞳验光的理想药物，而对16 ~18岁年龄段青少年可以直接小瞳验光。
应用推荐